貨號(hào)
產(chǎn)品規(guī)格
售價(jià)
備注
BN41897R-50ul
50ul
￥1486.00
交叉反應(yīng)：Human 推薦應(yīng)用：WB,ICC
BN41897R-100ul
100ul
￥2360.00
交叉反應(yīng)：Human 推薦應(yīng)用：WB,ICC
BN41897R-200ul
200ul
￥3490.00
交叉反應(yīng)：Human 推薦應(yīng)用：WB,ICC
產(chǎn)品描述
| 英文名稱(chēng) | VLDL Receptor |
| 中文名稱(chēng) | 極低密度脂蛋白受體抗體 |
| 別 名 | Very low density lipoprotein receptor; VLDL R; VLDLR; VLDL-R; VLDLRCH. |
| 研究領(lǐng)域 | 腫瘤 心血管 免疫學(xué) 神經(jīng)生物學(xué) 信號(hào)轉(zhuǎn)導(dǎo) |
| 抗體來(lái)源 | Rabbit |
| 克隆類(lèi)型 | Polyclonal |
| 交叉反應(yīng) | Human, |
| 產(chǎn)品應(yīng)用 | WB=1:500-2000 not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 93kDa |
| 細(xì)胞定位 | 細(xì)胞膜 |
| 性 狀 | Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human VLDL Receptor:551-650/873 <Extracellular> |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 儲(chǔ) 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| 保存條件 | Shipped at 4℃. Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. |
| PubMed | PubMed |
| 產(chǎn)品介紹 | VLDL (very low density lipoprotein) cholesterol is one of the three major types of cholesterol found in blood. VLDL receptor plays an essential role in triglyceride metabolism. It binds VLDL and transports it into cells by endocytosis. In order to be internalized, the receptor-ligand complexes must first cluster into clathrin coated pits. Binding to Reelin induces tyrosine phosphorylation of Dab1 and modulation of Tau phosphorylation. Function: Binds VLDL and transports it into cells by endocytosis. In order to be internalized, the receptor-ligand complexes must first cluster into clathrin-coated pits. Binding to Reelin induces tyrosine phosphorylation of Dab1 and modulation of Tau phosphorylation (By similarity). Subunit: Binds to the extracellular matrix protein Reelin. Interacts with VLDLR. Interacts with SNX17. Interacts with DAB1. Receptor for the minor-group human rhinoviruses (HRVs); binds protein VP1 through the second and third LDL-receptor class A domains. Subcellular Location: Membrane; Single-pass type I membrane protein. Membrane, clathrin-coated pit; Single-pass type I membrane protein. Tissue Specificity: Abundant in heart and skeletal muscle; also ovary and kidney; not in liver. Post-translational modifications: Ubiquitinated at Lys-839 by MYLIP leading to degradation. DISEASE: Defects in VLDLR are the cause of cerebellar ataxia mental retardation and dysequilibrium syndrome type 1 (CMARQ1) [MIM:224050]; also known as dysequilibrium syndrome (DES) or non-progressive cerebellar disorder with mental retardation. CMARQ1 is a congenital, non-progressive cerebellar ataxia associated with disturbed equilibrium, delayed ambulation, mental retardation and cerebellar hypoplasia. Additional features include short stature, strabismus, pes planus and, rarely, seizures. Similarity: Contains 3 EGF-like domains. Contains 8 LDL-receptor class A domains. Contains 6 LDL-receptor class B repeats. SWISS: P98155 Gene ID: 7436 Database links: Entrez Gene: 7436 Human Entrez Gene: 22359 Mouse Omim: 192977 Human SwissProt: P98155 Human SwissProt: P98156 Mouse Unigene: 370422 Human Unigene: 4141 Mouse Unigene: 9975 Rat Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
在線咨詢(xún)
English
